Phase 3 N=249 Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
Adult Kidney Wilms Tumor · Beckwith-Wiedemann Syndrome · Childhood Kidney Wilms Tumor
Primary: Event-Free Survival (EFS) — 0.82 Probability
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=380 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Stage III Kidney Wilms Tumor · Stage IV Kidney Wilms Tumor
Primary: Event Free Survival Probability — 0.79 Probability
Phase 3 N=808 Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
Stage I Kidney Wilms Tumor · Stage II Kidney Wilms Tumor · Stage III Kidney Wilms Tumor
Primary: Event Free Survival Probability — 0.88; 0.87; 0.88 Probability
Phase 2 N=291 Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
Childhood Renal Cell Carcinoma · Clear Cell Renal Cell Carcinoma · Clear Cell Sarcoma of the Kidney
Primary: Event-Free Survival of Patients With Diffuse Anaplastic Wilms' Tumor (DAWT) — 76.1; 25.0; 87.5 Percentage of 4-year OS — p=.0199
Phase 2 N=9 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
Hippel-Lindau Disease · Kidney Cancer
Primary: Number of Participants With a Renal Tumor Response — 0 participants
Phase 2 N=20 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
Childhood Hepatocellular Carcinoma · Papillary Thyroid Cancer · Previously Treated Childhood Rhabdomyosarcoma
Primary: Objective Response by RECIST Criteria v 1.1 — 10; 10; 0; 0 participants
Phase 2 N=102 BMS 247550 to Treat Kidney Cancer
Renal Cell Carcinoma
Primary: Response Rate — 1; 9.4; 12.6; 76.8 Percentage of participants
Phase 2 N=62 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
Pleuropulmonary Blastoma · Recurrent Malignant Peripheral Nerve Sheath Tumor · Recurrent Neuroblastoma
Primary: Objective Response by Response Evaluation Criteria in Solid Tumors Version 1.1 — 0.00; 6.25; 0.00; 0.00 Percent of participants
Phase 2 N=13 Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer
Renal Cell Carcinoma · Graft-Versus-Host Disease · Engraftment Syndrome
Primary: Clinical Regression of Metastatic Renal Cell Carcinoma (Partial Response (PR)) or Complete Remission of Tumor (Complete Response (CR)) — 0; 0; 8; 1 participants
N/A N=31 Radiosurgery in Treating Patients With Kidney Tumors
Kidney Cancer
Primary: Maximum Tolerated Dose of Radiosurgery — 48; 60 Gy
Phase 2 N=19 Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
Kidney Cancer
Primary: Progression-free Survival at 3 Months — 2.9 months
Phase 2 N=37 Phase II Study of Vandetanib in Individuals With Kidney Cancer
Renal Cancer · Von Hippel Lindau
Primary: Overall Response Rate. — 3; 0; 75; 0 percentage of participants
Phase 2 N=10 Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
Clear Cell Renal Cell Carcinoma · Recurrent Renal Cell Cancer · Stage IV Renal Cell Cancer
Primary: Overall Efficacy, Taking Into Account Both Objective Response and Meaningful Reductions in Tumor Burden That do Not Meet the RECIST Criteria for PR or CR (e.g., 5-30%…
Phase 2 N=64 Therapy for Children With Advanced Stage Neuroblastoma
Neuroblastoma
Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants
Phase 3 N=78 Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor
Stage I Adrenal Cortical Carcinoma AJCC v7 · Stage II Adrenal Cortical Carcinoma AJCC v7 · Stage III Adrenal Cortical Carcinoma AJCC v7
Primary: Five Year Event-free Survival (EFS) — 0.86; 0.53; 0.51 Estimated probability five year EFS — p=0.44
Phase 2 N=25 Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension
Chronic Kidney Diseases · Cystic Kidney Disease
Primary: Number of Participants With Change in Radiologist's Lesion Evaluation — 0; 11; 0; 1 Participants
Phase 2 N=10 Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
Leukemia, Acute Myelogenous (AML) · Leukemia, Acute Lymphocytic (ALL) · Leukemia, Chronic Myelogenous (CML)
Primary: Toxicity — 5 participants
Phase 2 N=19 Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors
Adenocarcinoma · Neoplasms
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs): Part 1 — 4; 5; 3; 7 participants
Phase 2 N=63 Contrast-enhanced Ultrasound of the Kidney
Chronic Kidney Disease · Cystic Kidney Disease
Primary: Number of Lesions With a Change in Radiologist's Evaluation — 24 lesions
Phase 2 N=9 Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors
GIST
Primary: Number of Participants With a Clinical Activity-radiographic Response — 0; 0; 0; 0 Participants
Phase 3 N=70 Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
Childhood Atypical Teratoid/Rhabdoid Tumor
Primary: Event-free Survival — 0.3401; 0.4500 Estimated probability
Phase 2 N=36 RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS
Nonmalignant Neoplasm · Tuberous Sclerosis · Lymphangioleimyomatosis
Primary: Objective Response Rate — 44.4 percentage of participants
Phase 2 N=94 Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
Metastatic Renal Cell Carcinoma
Primary: Proportion of Patients Alive and Progression-free at 8 Weeks — 0.70; 0.52 proportion of participants
Phase 2 N=73 RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
Advanced and Metastatic Silent Neuro-Endocrine Tumors · Carcinoma · Neuroendocrine
Primary: Percentage of Participants' Best Overall Response Rate at 12 Months - Per Protocol Set (PP) — 0.0; 0.0; 56.7; 43.3 percentage of participants
Phase 2 N=28 Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
Clear Cell Renal Cell Carcinoma · Recurrent Renal Cell Cancer · Stage IV Renal Cell Cancer
Primary: Confirmed Response Rate (Complete Response and Partial Response) as Assessed by RECIST 1.1 Criteria — 14; 7; 4 Participants
Phase 2 N=69 Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer
Chromophobe Renal Cell Carcinoma · Clear Cell Renal Cell Carcinoma · Papillary Renal Cell Carcinoma
Primary: Maximum Tolerated Dose (MTD) of BAY 43-9006 (Sorafenib)in Combination With Bevacizumab (Phase I) — 200 mg
Phase 2 N=23 Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas
Glioma
Primary: RAD001 Response Rate Based on 2D MRI Change From Baseline — 15 participants — p=<0.001
Phase 2 N=24 Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging
Kidney Cancer
Primary: 3D CEUS Generated Metrics in Kidney Mass: Wash_In_Slope — 7.60 AU/second
Phase 2 N=21 Neoadjuvant Pazopanib in Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Response Rate — 8 Participants
Phase 2 N=26 Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
Kidney Cancer
Primary: Progression Free Survival — 9.6 months